B.Grimm Pharma, the leading manufacturer and distributor of pharmaceuticals, nutraceuticals, and cosmeceuticals in Thailand, is part of B.Grimm’s Healthcare business, one of the three main pillars alongside B.Grimm Power, the listed company, and B.Grimm Industrial businesses. Offering holistic healthcare solutions covering every aspect of the pharmaceutical industry, B.Grimm Pharma has announced the relocation of its head office to the Alma Link building on Chidlom Road. Strategically situated for convenient access and well-connected to major thoroughfares, this move underscores the company’s commitment to accelerating its ongoing business expansion. Anticipating sustained growth, B.Grimm Pharma is poised to introduce 6 new medicinal products by 2024, covering a diverse range of four key therapeutic areas: 1. Cardiovascular system, 2. Central nervous system, 3. Musculoskeletal system, and 4. Gastrointestinal system. This initiative is particularly crucial given the rising prevalence of various health conditions across Thailand. The company remains steadfast in its dedication to developing high-quality pharmaceuticals and medical supplies, leveraging cutting-edge technology and innovation. By bolstering research and production capabilities to meet stringent international standards, B.Grimm Pharma aims to adapt to evolving customer needs while fostering greater access to essential medicines throughout society.
Dr. Harald Link, Chairman of B.Grimm, Highlighted the company’s enduring legacy and commitment to do business with compassion, spanning 146 years since its pioneering as the first manufacturer of European medicine in Thailand, dating back to the establishment of ‘Siam Dispensary’ in 1878. Embracing a philosophy deeply rooted in societal well-being, B.Grimm emphasized our noble mission of ensuring equitable access to quality healthcare products while alleviating the financial burdens of treatment for patients.
“B.Grimm’s long-standing dedication to societal well-being is unwavering. With a vision deeply rooted in providing equitable access to quality healthcare products, the company is poised to make a significant impact on healthcare accessibility and affordability. Our ambitious goal of reaching 4.5 million patients by 2030 underscores our resolute dedication to improving lives and shaping a healthier future for all.”
B.Grimm Pharma’s cutting-edge manufacturing and research facilities, manned by a team of expert pharmacists and scientists, guarantee top-notch quality and innovation. Certified to international standards such as PIC/S GMP and ISO 9001:2015, the facility exemplifies efficiency and excellence. Backed by a proficient sales and marketing team, B.Grimm Pharma, including its subsidiaries Unison, Medline, F.C.P., and All Research, stands ready to meet diverse customer needs promptly. Offering a wide array of products including medicines, medical supplies, food supplements, cosmeceuticals, and medical devices, B.Grimm Pharma remains dedicated to supporting the healthcare needs of all individuals.
Ms. Caroline Link, Co-Chairman of B.Grimm Pharma, looks ahead with optimism as the company embarks on a new chapter, stating, “The relocation of our headquarters to the Alma Link building signifies an exciting opportunity for B.Grimm Pharma. Introducing Mr. Kittisak Dumrongtananurak as the head of B.Grimm Pharma further reinforces our dedication to excellence. With his extensive experiences of over 30 years in the pharmaceutical industry, we are confident in his ability to lead the company towards achieving our vision for success. In response to the anticipated continuous growth of the company, this strategic movement reaffirms B.Grimm Pharma’s position as a leader in Thailand’s pharmaceutical industry.”
B.Grimm Pharma’s ongoing commitment to innovation and quality, along with its dedication to conducting business responsibly towards society. Regarding the relocation of the head office from its previous location on Ladkrabang Road to the centrally situated Alma Link building on Chidlom road, which boasts convenient access via mass transit. This strategic move represents an expansion of business opportunities, paving the way for B.Grimm Pharma to better accommodate its customers and partners.
Mr. Kittisak Dumrongtananurak, Head of B.Grimm Pharma, expresses his enthusiasm for the journey ahead, remarking, “Joining B.Grimm Pharma at this pivotal moment is an honor. With a foundation grounded in high quality, strategic planning, streamlined operations and cutting-edge technology, we are well-positioned to enhance access to quality healthcare products. Together with the dedicated team at B.Grimm Pharma, we will tirelessly pursue our mission to drive positive change in the healthcare landscape.”
The company remains steadfast focus on research, development, and production of therapeutic drugs to aid numerous individuals. In addition to the introduction of the first-to-market generic drugs scheduled for release this year, B.Grimm Pharma also has a substantial pipeline of pharmaceutical products undergoing the registration process. At B.Grimm Pharma, we’re dedicated to serving the public and society at large. Guided by ethical principles and a philosophy of doing business with compassion, we strive to enhance access to quality medicines for patients to uplift living standards and enhance the quality of life for individuals across society. Harnessing modern technology and fostering innovation in drug development and healthcare, B.Grimm Pharma stands at the forefront of advancing healthcare solutions that positively impact communities.
